Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck, Modifi
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Merck acquires Yale-spinout Modifi Bio in $1.3B deal
Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by biopharmaceutical giant Merck & Co. Inc. in a $1.3 billion deal, the companies announced Wednesday.
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.
4h
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi has agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to ...
5h
Merck & Company (MRK) Receives a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...
6d
Merck KGaA Trims Health Care And Life Sciences Targets, Eyes M&A
Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...
1d
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...
5d
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
6d
on MSN
Merck KGaA Shares Jump on Expectations of AI Boost
Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...
1d
on MSN
How Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4 billion dispute
"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.
PharmTech
7h
AAPS PharmSci 360: The Importance of HCP Analysis in Biomanufacturing
Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Modifi
RSV
New York Stock Exchange
MRK
clesrovimab
Feedback